Lexeo Therapeutics and Abivax seek Nasdaq listings in shrinking pre-Thanksgiving window for biotech IPOs
The gene therapy startup Lexeo Therapeutics and inflammatory disease biotech Abivax filed paperwork to go public Friday afternoon, as the pre-Thanksgiving IPO window shrinks and a government shutdown looms.
New York-based Lexeo and Paris-based Abivax would join about a dozen other drug developers in going public this year, aiming to trade on the Nasdaq under the tickers $LXEO and $ABVX, respectively.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.